These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

626 related items for PubMed ID: 19958778

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N.
    Nephrol Dial Transplant; 2023 Oct 31; 38(11):2503-2516. PubMed ID: 37309038
    [Abstract] [Full Text] [Related]

  • 24. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M, Simioni N, Masiero A.
    Minerva Endocrinol; 2009 Dec 31; 34(4):333-8. PubMed ID: 20046162
    [Abstract] [Full Text] [Related]

  • 25. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ, Sookoian S.
    J Infect; 2020 Aug 31; 81(2):276-281. PubMed ID: 32474043
    [Abstract] [Full Text] [Related]

  • 26. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

  • 27. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
    Cohn JN.
    Adv Ther; 2007 Feb 12; 24(6):1290-304. PubMed ID: 18165212
    [Abstract] [Full Text] [Related]

  • 28. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.
    J Am Soc Hypertens; 2012 Feb 12; 6(5):338-45. PubMed ID: 22995802
    [Abstract] [Full Text] [Related]

  • 29. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun 12; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 30. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
    Atlas SA.
    J Manag Care Pharm; 2007 Oct 12; 13(8 Suppl B):9-20. PubMed ID: 17970613
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L, Jakubowska A, Lizakowski S, Świetlik D, Rutkowski B.
    J Renin Angiotensin Aldosterone Syst; 2015 Mar 12; 16(1):145-52. PubMed ID: 25324423
    [Abstract] [Full Text] [Related]

  • 34. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status.
    Ma TK, Kam KK, Yan BP, Lam YY.
    Br J Pharmacol; 2010 Jul 12; 160(6):1273-92. PubMed ID: 20590619
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm.
    Schmieder RE.
    Clin Exp Hypertens; 2010 Jan 12; 32(1):35-42. PubMed ID: 20144071
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.